

Session 1c: Neurodegenerative Disorders and Other Emerging Areas

Moderator

Dr. Edwin George, MD, PhD, FAAN

Disclosures

I have nothing to disclose.

Disclaimer

My remarks reflect the views of the speaker and should not be construed to represent FDA's views or policies.

Objectives

- Review the current state of knowledge regarding the mechanisms of action of GLP-1R agonists and their therapeutic applications to neurodegenerative disorders, pain syndromes, and other central nervous system disorders.
- Discuss available scientific evidence on the clinical efficacy of GLP-1R agonists for treating various central nervous system disorders, including neurodegenerative diseases and pain syndromes.
- Consider the unique challenges such as knowledge gaps, clinical trial design, and biomarker development for each central nervous system disorder.

Speakers

- Dr. Nigel Greig will speak on
 - *Preclinical evidence of GLP-1 receptor activity in neurodegenerative disorders*
- Dr. Dilan Athauda will speak on
 - *Evidence for clinical benefit of GLP-1 receptor agonists in Parkinson's disease*
- Dr. Christian Hölscher will speak about clinical benefit of GLP-1 receptor agonists in Alzheimer's disease in
 - *Neuroprotection by GLP-1 class drugs correlates with BBB penetration*
- Dr. Alexandra Sinclair will speak on
 - *The effect of GLP-1RA exenatide on idiopathic intracranial hypertension*
- Dr. Laura Jawidzik will speak on
 - *Biomarkers in Drug Development*